Navigation Links
ORTHOCON® Announces U.S. Market Launch of HEMASORB®
Date:2/17/2011

IRVINGTON, N.Y., Feb. 17, 2011 /PRNewswire/ -- ORTHOCON, Inc., a developer of implantable products designed to stop the bleeding from and to deliver drugs to bone, today announced the U.S. launch of its first commercial product, the HEMASORB Absorbable Bone Hemostat Matrix.

The HEMASORB Absorbable Bone Hemostat Matrix is a ready to use, biocompatible, water resistant, and absorbable putty that is designed to rapidly stop bleeding when applied to damaged or cut bone. HEMASORB was cleared for market introduction by the U.S. Food and Drug Administration (FDA) via the 510(k) premarket notification process. In 2010, ORTHOCON conducted a limited market introduction of this product under its development name, ORTHOstat.

"We believe that HEMASORB is an innovative product that addresses a substantial market opportunity and has the potential to become a standard of care," said John J. Pacifico, President and Chief Executive Officer of ORTHOCON. "It is easy to use; it satisfies unmet needs and it is cost-effective."

Bleeding from cut bone is a common occurrence in many operative procedures. Excessive bleeding from bone during surgery may impair the surgeon's view of the operative field, may result in the need for blood transfusions and may be associated with post-operative complications. ORTHOCON estimates that over 3.5 million patients undergoing surgeries in the U.S. and Europe each year could benefit from the intra-operative use of HEMASORB.

"HEMASORB is the first commercial product that employs our proprietary Syntinate Technology Platform," commented Richard L. Kronenthal, Ph.D., ORTHOCON's Scientific Founder. "We are currently developing a pipeline of follow-on products that will complement Syntinate's utility as a bone hemostat by exploiting its unique potential to deliver drugs directly to bone."

The Syntinate Technology Platform incorporates biocompatible and absorbable solids and liquids to create a synthetic matrix that, when applied to bone, mechanically blocks bleeding. In addition, these constituents may act as drug reservoirs allowing for site specific and extended delivery of local anesthetics, anti-infective agents, and other drugs.

"We believe that our pipeline of products, beginning with HEMASORB, is very compelling and has the potential to create significant clinical and commercial value," concluded Mr. Pacifico. "We expect that the successful market launch of our HEMASORB Absorbable Bone Hemostat Matrix will prime the market for the future introduction of an array of innovative products."

About ORTHOCON

Founded in 2005, ORTHOCON develops, manufactures, markets, and sells implantable products designed to stop the bleeding from and to deliver drugs to bone.  

ORTHOCON is funded by leading international venture capital investment firms. The company occupies 8,000 square feet at its new, state-of-the-art facility in Irvington, New York.  For more information, please visit www.orthocon.com.


'/>"/>
SOURCE ORTHOCON, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. Alere Inc. Announces Fourth Quarter 2010 Results
5. Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock
6. 6th Annual New York Stem Cell Summit Announces Spinal Cord Injury Panel Participants
7. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results Teleconference and Webcast
8. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
9. Gen-Probe Announces $150 Million Stock Repurchase Plan
10. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
11. Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):